title: [Overactive bladder syndrome--a public health challenge].
abstract: Overactive bladder is a highly prevalent clinical syndrome affecting up to 17% of women. It is often associated with urodynamic detrusor overactivity, leads to embarrassment and is frequently under-diagnosed and insufficiently treated. Its pathophysiology is complex and the numerous treatment modalities, some of them of poor evidence, aim to improve quality of life. When physiotherapy fails, anticholinergics are recommended as first-line medical treatment. They can be combined with or replaced by beta3-adrenergic agonists whereas sacral neuromodulation or posterior tibia nerve stimulation are considered an efficient alternative. Addidtionally, cystoscopic injection of botulinum toxine in the bladder has recently been validated in Switzerland as a treatment option for idiopathic overactive bladder.
authors.forename: N
authors.initials: N
authors.lastname: Veit-Rubin
authors.forename: S
authors.initials: S
authors.lastname: Meyer
authors.forename: C
authors.initials: C
authors.lastname: Achtari
mesh_terms: D058667:Adrenergic beta-3 Receptor Agonists / Q000627:therapeutic use; D001905:Botulinum Toxins / Q000008:administration & dosage; D018680:Cholinergic Antagonists / Q000627:therapeutic use; D004599:Electric Stimulation Therapy / Q000379:methods; D005260:Female; D006801:Humans; D026741:Physical Therapy Modalities; D011634:Public Health; D011788:Quality of Life; D013557:Switzerland; D013979:Tibial Nerve; D053201:Urinary Bladder, Overactive / Q000453:epidemiology / Q000503:physiopathology / Q000628:therapy*
chemical_list: D058667:Adrenergic beta-3 Receptor Agonists; D018680:Cholinergic Antagonists; D001905:Botulinum Toxins